Literature DB >> 1332035

Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

T Janáky1, A Juhász, Z Rékási, P Serfözö, J Pinski, L Bokser, G Srkalovic, S Milovanovic, T W Redding, G Halmos.   

Abstract

Five hexapeptide and heptapeptide analogs of luteinizing hormone-releasing hormone (LH-RH) were synthesized for use as carriers for cytotoxic compounds. These short analogs were expected to enhance target selectivity of the antineoplastic agents linked to them. Native LH-RH-(3-9) and LH-RH-(4-9) containing D-lysine and D-ornithine at position 6 were amidated with ethylamine and acylated on the N terminus. The receptor-binding affinity of one hexapeptide carrier AJ-41 (Ac-Ser-Tyr-D-Lys-Leu-Arg-Pro-NH-Et) to human breast cancer cell membranes was similar to that of [D-Trp6]LH-RH. Alkylating nitrogen mustards (melphalan, Ac-melphalan), anthraquinone derivatives including anticancer antibiotic doxorubicin, antimetabolite (methotrexate), and cisplatin-like platinum complex were linked to these peptides through their omega-amino group at position 6. The hybrid molecules showed no LH-RH agonistic activity in vitro and in vivo but had nontypical antagonistic effects on pituitary cells in vitro at the doses tested. These analogs showed a wide range of receptor-binding affinities to rat pituitaries and cell membranes of human breast cancer and rat Dunning prostate cancer. Several of these conjugates exerted some cytotoxic effects on MCF-7 breast cancer cell line.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332035      PMCID: PMC50306          DOI: 10.1073/pnas.89.21.10203

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective.

Authors:  M J Karten; J E Rivier
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

2.  Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.

Authors:  R I Nicholson; K J Walker; R F Walker; G F Read; A Turkes; J F Robertson; R W Blamey
Journal:  Horm Res       Date:  1989

3.  Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes.

Authors:  M Fekete; S Bajusz; K Groot; V J Csernus; A V Schally
Journal:  Endocrinology       Date:  1989-02       Impact factor: 4.736

4.  Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines.

Authors:  N Harris; C Dutlow; K Eidne; K W Dong; J Roberts; R Millar
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

5.  Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

Authors:  S Bajusz; T Janaky; V J Csernus; L Bokser; M Fekete; G Srkalovic; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.

Authors:  S Bajusz; T Janaky; V J Csernus; L Bokser; M Fekete; G Srkalovic; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.

Authors:  V K Sondak; C A Bertelsen; N Tanigawa; S U Hildebrand-Zanki; D L Morton; E L Korn; D H Kern
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

8.  Studies with fragments of a highly active analogue of luteinizing hormone releasing hormone.

Authors:  J Sandow; W König
Journal:  J Endocrinol       Date:  1979-05       Impact factor: 4.286

9.  Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.

Authors:  K Szepeshazi; A V Schally; A Juhasz; A Nagy; T Janaky
Journal:  Anticancer Drugs       Date:  1992-04       Impact factor: 2.248

10.  The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.

Authors:  A Qayum; W Gullick; R C Clayton; K Sikora; J Waxman
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more
  4 in total

1.  Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

Authors:  A Nagy; A V Schally; P Armatis; K Szepeshazi; G Halmos; M Kovacs; M Zarandi; K Groot; M Miyazaki; A Jungwirth; J Horvath
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.

Authors:  A Nagy; B Szoke; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

3.  Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.

Authors:  A M Otto; N A Kratochwil; H Eggers; P J Bednarski
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 4.  Exploring the cellular accumulation of metal complexes.

Authors:  Cindy A Puckett; Russell J Ernst; Jacqueline K Barton
Journal:  Dalton Trans       Date:  2009-12-23       Impact factor: 4.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.